Fozia Noor

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3109061/publications.pdf

Version: 2024-02-01

430874 552781 1,554 26 18 26 citations h-index g-index papers 26 26 26 2505 citing authors all docs docs citations times ranked

| # | Article | IF | Citations |
|----|---|------|-----------|
| 1 | Proteomic Characterization of Primary Mouse Hepatocytes in Collagen Monolayer and Sandwich Culture. Journal of Cellular Biochemistry, 2018, 119, 447-454. | 2.6 | 2 |
| 2 | Hepatocytes of Wistar and Sprague Dawley rats differ significantly in their central metabolism. Journal of Cellular Biochemistry, 2018, 119, 909-917. | 2.6 | 7 |
| 3 | Towards a 21st-century roadmap for biomedical research and drug discovery: consensus report and recommendations. Drug Discovery Today, 2017, 22, 327-339. | 6.4 | 64 |
| 4 | Accessing 3D microtissue metabolism: Lactate and oxygen monitoring in hepatocyte spheroids. Biosensors and Bioelectronics, 2017, 87, 941-948. | 10.1 | 83 |
| 5 | Metabolic fate of desomorphine elucidated using rat urine, pooled human liver preparations, and human hepatocyte cultures as well as its detectability using standard urine screening approaches. Analytical and Bioanalytical Chemistry, 2016, 408, 6283-6294. | 3.7 | 34 |
| 6 | Novel human hepatic organoid model enables testing of drug-induced liver fibrosis inÂvitro. Biomaterials, 2016, 78, 1-10. | 11.4 | 181 |
| 7 | <i>In Silico</i> Modeling for the Prediction of Dose and Pathway-Related Adverse Effects in Humans From <i>In Vitro</i> Repeated-Dose Studies. Toxicological Sciences, 2016, 149, 55-66. | 3.1 | 14 |
| 8 | A shift in paradigm towards human biologyâ€based systems for cholestaticâ€liver diseases. Journal of Physiology, 2015, 593, 5043-5055. | 2.9 | 18 |
| 9 | State-of-the-art of 3D cultures (organs-on-a-chip) in safety testing and pathophysiology. ALTEX: Alternatives To Animal Experimentation, 2014, 31, 441-477. | 1.5 | 166 |
| 10 | 3D organotypic HepaRG cultures as in vitro model for acute and repeated dose toxicity studies. Toxicology in Vitro, 2014, 28, 104-112. | 2.4 | 131 |
| 11 | Longâ€term maintenance of HepaRG cells in serumâ€free conditions and application in a repeated dose study. Journal of Applied Toxicology, 2014, 34, 1078-1086. | 2.8 | 33 |
| 12 | 3D Organotypic Cultures of Human HepaRG Cells: A Tool for In Vitro Toxicity Studies. Toxicological Sciences, 2013, 133, 67-78. | 3.1 | 197 |
| 13 | Real-time in situ viability assessment in a 3D bioreactor with liver cells using resazurin assay. Cytotechnology, 2013, 65, 297-305. | 1.6 | 14 |
| 14 | 3D Hepatic In Vitro Models as Tools for Toxicity Studies. Current Tissue Engineering, 2013, 2, 78-89. | 0.2 | 6 |
| 15 | Metabolomics in toxicology and preclinical research. ALTEX: Alternatives To Animal Experimentation, 2013, 30, 209-225. | 1.5 | 164 |
| 16 | Doxorubicin Increases Oxidative Metabolism in HL-1 Cardiomyocytes as Shown by 13C Metabolic Flux Analysis. Toxicological Sciences, 2012, 125, 595-606. | 3.1 | 36 |
| 17 | Biotransformation of diclofenac and effects on the metabolome of primary human hepatocytes upon repeated dose exposure. European Journal of Pharmaceutical Sciences, 2012, 45, 716-724. | 4.0 | 19 |
| 18 | Metabolic flux analysis gives an insight on verapamil induced changes in central metabolism of HL-1 cells. Journal of Biotechnology, 2011, 155, 299-307. | 3.8 | 26 |

| # | Article | IF | CITATION |
|----|--|-----|----------|
| 19 | Toward Preclinical Predictive Drug Testing for Metabolism and Hepatotoxicity by Using ⟨i>In Vitro⟨ i> Models Derived from Human Embryonic Stem Cells and Human Cell Lines — A Report on the Vitrocellomics EU-project. ATLA Alternatives To Laboratory Animals, 2011, 39, 147-171. | 1.0 | 38 |
| 20 | Metabolic profiling using HPLC allows classification of drugs according to their mechanisms of action in HL-1 cardiomyocytes. Toxicology and Applied Pharmacology, 2011, 252, 183-191. | 2.8 | 19 |
| 21 | In-depth physiological characterization of primary human hepatocytes in a 3D hollow-fiber bioreactor. Journal of Tissue Engineering and Regenerative Medicine, 2011, 5, e207-e218. | 2.7 | 37 |
| 22 | Cardiotoxicity testing using pluripotent stem cellâ€derived human cardiomyocytes and stateâ€ofâ€theâ€art bioanalytics: a review. Journal of Applied Toxicology, 2011, 31, 191-205. | 2.8 | 71 |
| 23 | High throughput, non-invasive and dynamic toxicity screening on adherent cells using respiratory measurements. Toxicology in Vitro, 2010, 24, 686-694. | 2.4 | 29 |
| 24 | An integrated approach to improved toxicity prediction for the safety assessment during preclinical drug development using Hep G2 cells. Toxicology and Applied Pharmacology, 2009, 237, 221-231. | 2.8 | 49 |
| 25 | Effects of drugs in subtoxic concentrations on the metabolic fluxes in human hepatoma cell line Hep G2. Toxicology and Applied Pharmacology, 2009, 240, 327-336. | 2.8 | 49 |
| 26 | Enhanced Cellular Uptake and Cytotoxicity Studies of Organometallic Bioconjugates of the NLS Peptide in Hep G2 Cells. ChemBioChem, 2009, 10, 493-502. | 2.6 | 67 |